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Interstitial lung diseases (ILDs) are a diverse group of pulmonary disorders characterized by
various patterns of inflammation and fibrosis in the interstitium of the lung. Because injury
and/or regeneration of type II pneumocytes are prominent histological features of ILDs,
substances derived from type II pneumocytes have been the focus of research investigating
potential biomarkers for ILD. One important biomarker for ILD is the high-molecular-weight
glycoprotein, Krebs von den Lungen-6 (KL-6). KL-6 is now classified as a human MUC1 mucin
protein, and regenerating type II pneumocytes are the primary cellular source of KL-6/MUC1 in
the affected lungs of patients with ILD. KL-6/MUC1 is detectable in the serum of patients with
ILD, and extensive investigations performed primarily in Japan have revealed that serum KL-6/
MUC1 is elevated in 70–100% of patients with various ILDs, including idiopathic interstitial
pneumonias, collagen vascular disease-associated interstitial pneumonia, hypersensitivity
pneumonia, radiation pneumonitis, drug-induced ILDs, acute respiratory distress syndrome,
pulmonary sarcoidosis, and pulmonary alveolar proteinosis. The results from these various
studies have supported the utility of KL-6/MUC1 as a serum biomarker for detecting these
various ILDs. Moreover, KL-6/MUC1 serum levels have been demonstrated to be useful for
evaluating disease activity and predicting the clinical outcomes of various ILD types. Based on
these observations, we believe that KL-6/MUC1 is currently one of the best and most reliable
serum biomarkers available for ILD management.
& 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.anese Respiratory Society. Published by Elsevier B.V. All rights reserved.
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Interstitial lung diseases (ILDs) are a diverse group of
pulmonary disorders characterized by various patterns of
inflammation and fibrosis in the interstitium of the lung,
including idiopathic interstitial pneumonias (IIPs), collagen
vascular disease-associated interstitial pneumonia (CVD-IP),
hypersensitivity pneumonia (HP), radiation pneumonitis (RP),
drug-induced ILDs (D-ILDs), acute respiratory distress syn-
drome (ARDS), and sarcoidosis [1–4]. Moreover, based on
histological features, IIPs have been further classified into
several types, including idiopathic pulmonary fibrosis (IPF)
with the histopathology of usual interstitial pneumonia (UIP)
and nonspecific interstitial pneumonia (NSIP).
High-resolution computed tomography (HRCT), broncho-
scopic examination, and/or surgical lung biopsy (SLB) are
fundamental steps required to make a definite diagnosis of
various ILDs, including IIPs [4–6]. Furthermore, serial lung
function testing is generally used to monitor disease activity
and/or predict the prognosis in patients with ILDs [7]. However,
these examinations require specific medical facilities and may
result in considerable discomfort to patients. Thus, the
identification of serum biomarkers for ILDs would greatly
improve current diagnostic methods. Serum biomarkers offer
several advantages over other methods, including being gen-
erally easy to perform, inexpensive, reproducible, and less
invasive. To date, various serum biomarkers have been tested
for their use in ILDs [8–13]. Among these, biomarkers derived
from type II pneumocytes have been of particular interest,
because ILDs show a common pathophysiological development,
i.e., type II pneumocyte injury or remodeling [8]. The most
widely used biomarkers for ILDs derived from type II pneumo-
cytes are KL-6 and 2 surfactant proteins, SP-A and SP-D. These 3
biomarkers have been studied independently by 2 Japanese
research groups (Hiroshima University and Sapporo Medical
University) and are currently in wide clinical use in Japan.
Lactate dehydrogenase (LDH) has also been used as a biomarkerfor ILDs in Japan; however, LDH serum levels are not specific for
lung damage and have been superseded by KL-6, SP-A, and SP-D
[8]. This review, from the research group that discovered KL-6,
discusses the clinical application of KL-6 as one of the most
promising serum biomarkers for patients with various types
of ILDs.2. From discovery to clinical application: the
novel glycoprotein, KL-6
A murine IgG1 monoclonal antibody (mAb) was developed to
recognize a sialylated sugar chain, designated as Krebs von
den Lungen-6 (KL-6), by immunizing amousewith the human
lung adenocarcinoma cell line VMRC-LCR [14]. KL-6 was first
suggested as a serum tumor biomarker for pulmonary, breast,
and pancreatic cancers. However, the diagnostic accuracy of
KL-6 as a tumor marker was found to be inferior to that of
carcinoembryonic antigen (CEA) based on the high rate of
false positive cases in patients with pulmonary fibrosis.
Further investigations in our laboratory revealed the possibi-
lity of KL-6 as a biomarker for ILDs, because patients with
benign noninterstitial lung disease did not show a significant
elevation in the serum levels of KL-6 [15]. A cooperative study
on KL-6 as a serum biomarker was initiated with the
diagnostic division of Eidia Co., Ltd. (Tokyo, Japan) in 1992.
The findings of this study led to the development of an
enzyme-linked immunosorbent assay (ELISA) that enabled
the determination of the absolute amount of KL-6 in samples
collected in clinical practice. KL-6 has been approved by
Japan’s Health Insurance Program as a diagnostic marker for
ILDs since 1999, and KL-6 levels are examined in more than
2,000,000 samples per year in Japan. A chemiluminescent
enzyme immunoassay (CLEIA) system has now been devel-
oped that can measure serum KL-6 levels within 1 h in
ordinary Japanese clinical settings. However, the measure-
ment of KL-6 is currently not possible for clinical practices in
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from SCETI Bioscience Export Co., Ltd. (Tokyo, Japan), under
contract with Edia Co., Ltd., is available for research purposes
only.3. Biochemical and biological properties of KL-6
As described above, we developed an mAb to recognize an
undefined high-molecular-weight (200 kDa) glycoprotein de-
signated KL-6. Using this anti-KL-6 mAb, we purified KL-6
from the culture medium of human breast cancer YMB-S
cells. Because sialidase digestion or periodate oxidation of
KL-6 reduced the binding of anti-KL-6 mAb to KL-6, the
epitope on KL-6 was suggested to be a carbohydrate-contain-
ing sialic acid [14]. Subsequently, KL-6 was classified as
‘‘Cluster 9 (MUC1)’’ at the Third World International
Workshop of the International Association for the Study of
Lung Cancer on lung tumor and differentiation antigens
according to the results of immunohistochemical and flow
cytometry studies, although the precise epitope structure
recognized by the anti-KL-6 mAb was unclear [16,17]. A
previous study from our laboratory clearly demonstrated that
KL-6 was a submolecule of MUC1 based on the results
of a carbohydrate composition analysis [18]. In accordance
with these different observations, KL-6/MUC1 is commonly
used to denote the KL-6 molecule. Recently, the possible
carbohydrate epitopes of the anti-KL-6 mAb have been
reported to be novel O-linked glycans containing 60sulfo-Gal/
GalNAc of MUC1 [19].
MUC1 (episialin, polymorphic epithelial mucin) is a large
glycoprotein containing 3 domains: (1) a cytoplasmic tail, (2) a
single transmembrane region, and (3) an extracellular domain
(Fig. 1a). The extracellular region of MUC1 contains sites of O-
and N-linked glycosylation and a variable number tandem
repeat (VNTR) domain with 20–100 repeats of a 20-amino acid
sequence [20,21]. MUC1 has an extended, rigid structure
protruding 200–500 nm above the plasma membrane and is
found on the apical surface of normal glandular epithelial
cells. The MUC1 extracellular domain can be shed into the
pulmonary epithelial lining fluid (ELF) through the action of
TNF-a converting enzyme (TACE; also called a disintegrin and
metalloproteinase 17 [ADAM17]) and potentially ADAM9
[21,22]. In addition, some soluble MUC1 may result from
alternative splicing. Transfection studies have revealed that
MUC1 reduces cell–cell and cell–extracellular matrix (ECM)
interactions, decreases cell aggregation, and prevents E-
cadherin-mediated cell–cell adhesion and integrin-mediated
cell–ECM adhesion. Previous studies have demonstrated that
E-cadherin can be functionally suppressed by MUC1 over-
expression [23] and that anti-KL-6/MUC1 mAb induces the
capping of MUC1 and facilitates E-cadherin-mediated cell–cell
interactions [24].
As described below in this review, the clinical importance of
KL-6/MUC1 in the management of ILD has been established.
However, very little is known about the pathophysiological
role of KL-6/MUC1 in patients with ILDs. Previous studies
from our laboratory demonstrated that purified KL-6/MUC1
has chemotactic and anti-apoptotic effects on fibroblasts and
that the proliferative and anti-apoptotic effects of KL-6/MUC1are additive to those of transforming growth factor-b [18,25].
These results support the hypothesis that KL-6/MUC1 is one
of the key molecules involved in the intra-alveolar fibrotic
process and pulmonary fibrosis. Moreover, these results
indicate that KL-6/MUC1 may become a promising molecular
target for the treatment of pulmonary fibrosis.4. Expression of KL-6/MUC1 in tissues
Several studies have evaluated the expression of KL-6/MUC1
using immunohistochemistry (Table 1) [14,15,26]. KL-6/MUC1
is moderately expressed in type II pneumocytes and respira-
tory bronchiolar epithelial cells and only weakly expressed in
basal cells of the terminal bronchiolar epithelium of normal
lung tissues. On the other hand, type I pneumocytes, goblet
cells, and mucous cells of the bronchial glands do not express
KL-6/MUC1. Furthermore, KL-6/MUC1 is not expressed by the
epithelial cells of the stomach, small intestine, or large
intestine, with the exception of the fundic gland cells in the
stomach. In addition to strong expression in lung, pancreatic,
and breast cancer tissues, KL-6/MUC1 is strongly expressed by
atypical and/or regenerating type II pneumocytes in tissue
sections obtained from patients with ILDs [14,27,28]. Ohtsuki
et al. reported linear and continuous staining for KL-6/MUC1
on the cell surface of regenerating type II pneumocytes in
patients with IPF or NSIP, but only discontinuous staining in
normal lung tissues (Fig. 1b) [29,30]. KL-6/MUC1 is also
strongly expressed in areas of destruction in the pulmonary
structures, loose stroma, and endothelial cells of lymph
vessels, as well as the contents of these regions [31]. Weak
to moderate expression was also observed in several cancer
tissues, such as stomach, colon, and hepatocellular tumors
[32–34]. KL-6/MUC1 is also expressed in the premature lung
during the early weeks of pregnancy, and its expression
persists even after lung maturation [35,36].5. Positive rates of KL-6/MUC1 serum levels
in various diseases
A clinical cut-off value of 500 U/mL has been established for
distinguishing patients with ILDs from healthy subjects and
patients with lung diseases other than ILDs [37]. KL-6/MUC1
serum levels higher than the cut-off value have been
observed in more than 70% of patients with ILDs, including
IIPs, CVD-IP, HP, RP, D-ILDs, ARDS, pulmonary sarcoidosis, and
pulmonary alveolar proteinosis (PAP, Table 2) [15,38–50].
Interestingly, less than 10% of patients with alveolar pneu-
monia tested positive for KL-6/MUC1. Meanwhile, 28% of
patients with active pulmonary tuberculosis and 2.6% of
patients with inactive pulmonary tuberculosis test positive
for KL-6/MUC1, with most positive patients showing wide-
spread involvement of the lungs [51]. Patients with advanced
stages of lung, pancreatic, and breast cancers showed an
almost 50% positive rate [14,27,52–54]. However, the positive
rate was low for gastric, hepatocellular, colon, and rectal
cancers, and for hepatitis, liver cirrhosis, and pancreatitis.
Length, 200–500 nm
Transmembrane region
10–30 nmVariable number of tandem repeats (VNTRs)
Cleavage site
N-linked carbohydrate
GSTAPPAHGVTSAPDTRPAP
25–125 repeats of a 20-amino acid sequence
O-linked carbohydrate
Normal lung Affected lung
Enhancement of permeability
KL-6 Type II alveolar epithelial cell
Type I alveolar epithelial cell
Blood vessel
Cytoplasmic
tail
Increase in KL-6 production
by regenerating type II
pneumocytes
Alveolar basement membrane
Fig. 1 – (a) Structure of MUC1. MUC1 is a large glycoprotein that contains 3 domains: (1) a cytoplasmic tail, (2) a single
transmembrane region, and (3) an extracellular domain. The extracellular region contains sites of O- and N-linked glycosylation
and a variable number tandem repeat (VNTR) domain of 20–100 repeats of a 20-amino acid sequence, (b) KL-6/MUC1 expression
on the surface of type II pneumocytes. A discontinuous positive reaction (arrows) with anti-KL-6 antibody was observed in
presumably normal lung tissue from a case of pneumothorax (left panel; magnification, 400). Note the distinct dome-shaped
positivity of the type II alveolar cells on staining with KL-6 antibody (inset at left panel; magnification, 800). Linear and
continuous staining for KL-6/MUC1 was observed on the cell surface of regenerating type II pneumocytes in patients with IPF
(middle panel; magnification, 400). Immunoelectron microscopic findings revealed that the reaction with anti-KL-6 antibody
exhibits a linear pattern on the cell surface of type II pneumocytes in a patient with NSIP (right panel; magnification, 400). Note
that positive surface granular structures are approximately 100–200 nm in diameter. Scale bar ¼ 0.5 lm. Modified from [29], with
permission from the publisher. (c) Mechanism for the blood uptake of KL-6/MUC1. The increased serum levels of KL-6 in patients
with ILDs may be due to an increase in KL-6 production by regenerating alveolar type II pneumocytes and/or enhanced
permeability following the destruction of alveolar capillaries in the affected lung.
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Table 1 – KL-6 expression in various tissues.
Modified from [26], with permission from the publisher.
Negative Positive
Weak Moderate Strong
Normal
Lung Type I pneumocytes Basal cells of
terminal bronchi
Type II pneumocytes
Ciliated bronchial cells Respiratory bronchi
epithelial cells
Goblet cells Serous cells of the
bronchial glandsMucous cells of the bronchial
gland
Others Surface mucous cells of the
stomach
Fundic gland cells of the
stomach
Pyloric cells of the stomach Ductal epithelial cells of
the mammary gland
Epithelial cells of the
duodenum
Ductal epithelial cells of
the pancreas
Epithelial cells of the rectum
Epithelial cells of the colon
Acinar cells of the pancreas
Leukocytes
Red blood cells
Interstitial lung disease Granuloma Regenerating type II
pneumocytesGiant cells
Malignant cells Some malignant cells Most malignant cells Lung cancer
Pancreatic cancer
Breast cancer
Table 2 – Positive rate of KL-6 in various diseases.
Modified from [26], with permission from the publisher.
Positive rate
0–10% 10–30% 30–70% 70–100%
Benign disease
Lung Alveolar
pneumonia
Pulmonary
tuberculosis (total)
Diffuse panbronchitis Idiopathic interstitial pneumonias
Bronchial asthma Pneumoconiosis Sarcoidosis Collagen vascular disease-
associated interstitial pneumonitis
COPD Pulmonary tuberculosis with wide-
spread involvement of the lung field
Hypersensitivity pneumonitis
Bronchiectasis Radiation pneumonitis
Pneumoconiosis Drug-induced pneumonitis
Acute respiratory distress syndrome
Pulmonary sarcoidosis pulmonary
alveolar proteinosis
Others Hepatitis
Liver cirrhosis
Pancreatitis
Cholecystitis
Malignancies
Gastric cancer Lung cancer
Colon cancer Pancreatic cancer
Rectal cancer Breast cancer
Hepatic cancer
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levels
More than 50 papers investigating the clinical significance of
KL-6 in various types of ILDs have been published from our
research groups, and more than 350 papers on KL-6/MUC1
can be found in PubMed, with an increasing number of
reports from international groups of researchers [8]. The data
from these reports suggest that KL-6/MUC1 serum levels are
useful for (1) detecting the presence of disease, (2) evaluating
disease activity, and (3) predicting clinical outcomes in
various types of ILDs. The clinical utility of KL-6/MUC1 in
various types of ILDs is summarized in Table 3.
6.1. IIPs
The first report from our laboratory describing KL-6/MUC1 serum
levels demonstrated that KL-6/MUC1 serum levels in patients
with various types of ILDswere significantly higher than those of
healthy control subjects [15]. KL-6/MUC1 serum levels were
found to be particularly high in IIP patientswith a positive uptake
of 67Ga-citrate in their diseased lung. Furthermore, a significant
positive correlation was observed between changes in KL-6/
MUC1 serum levels and the subjective and objective signs of
disease activity in patients whose clinical courses were followed.
In another study, the KL-6/MUC1 serum levels in 33 patientswith
ILDs (21 patients with IPF and 12 with CVD-IP) were compared to
82 control subjects (70 healthy controls and 12 patients with
bacterial pneumonia) [46]. A receiver operating characteristic
(ROC) curve drawn in this study revealed the superiority of KL-6/
MUC1 to SP-A, SP-D, andMCP-1 as a diagnosticmarker of ILDs, as
revealed by the diagnostic accuracy, sensitivity, specificity, and
likelihood ratios. Based on these data, KL-6/MUC1 is thought to
be useful for distinguishing most ILDs from other benign lung
diseases, such as alveolar pneumonia. However, KL-6/MUC1
serum levels are elevated in 70–100% of patients with ILDs and
therefore cannot be used to differentiate patients with IPF from
those with NSIPs [55]. A detailed analysis of the relationship
between KL-6/MUC1 serum levels and disease extent on HRCT in
patients with NSIP revealed that KL-6/MUC1 serum levels are
significantly correlated with the extent of interstitial disease
[25,56,57]. Follow-up CT and changes in KL-6/MUC1 serum levelsTable 3 – Clinical utility of KL-6 in various types of ILDs.
Disease Detection of disease Evaluatio
Utility References Utility
IIPs þþ [15,41,46,55] þþ
CVD-IP þþ [41,46,60–64,66–69] þþ
HP þþ [15,41,78,80,81] þþ
RP þ [15,38,82,83] þþ
D-ILDs þ [47,86] þþ
ARDS þþ [49,87,92] þþ
IIPs: idiopathic interstitial pneumonias; CVD-IP: collagen vascular disease
RP: radiation pneumonitis; D-ILDs: drug-induced interstitial lung dise
þ: moderate utility NE: not evaluated.after treatment showed that the percent change in disease extent
is reflected in the levels of KL-6/MUC1. Together, these observa-
tions indicate that KL-6/MUC1 serum levels may reflect the
presence of fibrotic lung lesions accompanied by regenerating
epithelial cells.
Acute exacerbation is a critical prognostic factor that
shortens the survival period of patients with IPF. A small
study followed 14 patients with rapidly progressive IPF who
received weekly high-dose corticosteroid pulse therapy for at
least 3 weeks [43]. KL-6/MUC1 serum levels significantly
decreased in survivors, but tended to increase in nonsurvi-
vors, suggesting that changes in KL-6/MUC1 serum levels can
predict the efficacy of high-dose corticosteroid pulse therapy.
However, this study was conducted prior to the 2002 ATS/ERS
classification of ILDs; therefore, the diagnosis of some of
these patients may be different from what is now accepted.
Elevated serum KL-6/MUC1 (KL-6/MUC1 levelsZ1000 U/mL)
in IPF patients at the initial visit were associated with
increased mortality [48]. Satoh et al. also reported that the
progression of the disease was significantly faster in patients
with ILDs whose KL-6/MUC1 levels were 1000 U/mL or more at
the initial measurement than in patients whose KL-6/MUC1
levels were less than 1000 U/mL [58].6.2. CVD-IP
ILDs are common manifestations in patients with collagen
vascular disease (CVD), with an overall incidence estimated at
15% [59]. In a study conducted in our laboratory, KL-6/MUC1
serum levels were shown to be elevated in patients with CVD-
IP compared to those of control subjects (healthy subjects and
patients with bacterial pneumonia) [46]. In another study
from our laboratory, the serum levels of KL-6/MUC1 were
measured in 177 patients with rheumatoid arthritis. The
results showed that an increase in KL-6/MUC1 serum levels
was correlated with the presence of active CVD-IP [60].
Nakajima et al. evaluated the serum levels of KL-6/MUC1 in
patients with CVD with or without ILDs and demonstrated
that KL-6/MUC1 serum levels are useful markers in the
diagnosis and evaluation of CVD-IP disease activity [61]. The
utility of KL-6/MUC1 as a serum biomarker to detect ILDs and
evaluate disease activity in patients with systemic sclerosisn of disease activity Prediction of the prognosis
References Utility References
[41,43] þþ [48,58]
[41,61–69] NE
[41,78,79] NE
[38,39,82,83] þ [84]
[47,86] þþ [47,86]
[49,87,92] þþ [50,87,88]
-associated interstitial pneumonia; HP: hypersensitivity pneumonia;
ases; ARDS: acute respiratory distress syndrome; þþ: high utility,
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been reported in several publications [62–69]. Furthermore,
the serum levels of KL-6/MUC1 in patients with SSc are
correlated with functional lung impairment, as expressed by
diffusing capacity for carbon monoxide (DLCO) reduction [69].
Glucocorticosteroids, immunosuppressants, and biological
agents are widely used for the treatment of CVD, particularly
in rheumatoid arthritis [70,71]. However, these therapies
sometimes cause adverse effects, such as the occurrence of
opportunistic infection. One such infection is Pneumocystis
jiroveci pneumonia (PCP). This infection results in the
appearance of ground-glass opacity on HRCT imaging and
resembles acute exacerbation of ILD. Several reports demon-
strate that KL-6/MUC1 serum levels are elevated in patients
with PCP [72–75]. However, b-D-glucanmay be more reliable as
a serum diagnostic marker for PCP than KL-6/MUC1, since
KL-6/MUC1 is too sensitive for underlying ILDs. Therefore,
KL-6/MUC1 can be used to determine the extent of damaged
alveolar epithelium and alveolar–capillary permeability,
whereas b-D-glucan is a marker for fungal volume.
6.3. HP
HP, also known as extrinsic allergic alveolitis (EAA), is an
immunologically mediated lung disease induced by the inhala-
tion of antigens present in various systemic organs [76]. The
clinical manifestation of HP can be divided into acute, subacute,
or chronic types [77]. In patients with summer-type acute HP,
KL-6/MUC1 serum levels are elevated [15,41]. Takahashi et al.
evaluated KL-6/MUC1 serum levels in 272 farmers in a daily
farming community and showed that KL-6/MUC1 serum levels
were significantly higher in patients with farmer’s lung disease
(FLD) compared to farmers without FLD. In patients with FLD,
KL-6/MUC1 serum levels were correlated with the activity of the
disease [78]. Several reports demonstrate that KL-6/MUC1
serum levels are useful for evaluating disease activity in
patients with HP caused by spores of the Japanese mushroom
[79,80]. Inase et al. reported that KL-6/MUC1 serum levels were
also elevated in cases of chronic HP with the potential to
develop end-stage lung fibrosis similar to IPF [81].
6.4. RP
RP is a common complication that restricts the use of radio-
therapy against lung cancer and sometimes leads to progressive
respiratory failure or even death. The utility of KL-6/MUC1 in
distinguishing RP from lung cancer is limited. However, the
serum levels of KL-6/MUC1 are useful for the early diagnosis of
RP in patients with lung cancer who receive radiation therapy
[38,39]. Goto et al. monitored KL-6/MUC1 serum levels in
patients with lung cancer at multiple time points after the start
of radiation therapy and showed a correlation between the
changes in serum KL-6/MUC1 levels and the clinical course of
RP [82]. Furthermore, patients whose KL-6/MUC1 serum levels
rose more than 1.5 times higher than baseline levels showed a
trend toward the development of severe life-threatening RP
[83,84]. Yamashita et al. retrospectively evaluated the incidence
rate and risk factors of severe RP after stereotactic body
radiotherapy (SBRT) for 117 patients with lung cancers. Grade
4–5 RP was observed in 9 patients (7.7%), and a correlation wasfound between the incidence of grade 4–5 RP and higher serum
KL-6/MUC1 levels [84].
6.5. D-ILDs
Various agents can cause pulmonary toxicity, including ILDs,
which often results in a fatal outcome. Moreover, a high
incidence of ILDs is reported in patients with advanced non-
small cell lung cancer (NSCLC) treated with epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKIs), parti-
cularly in Japanese populations [85]. The serum levels of KL-6/
MUC1 were examined in 30 patients with D-ILDs who were
classified into 4 different HRCT patterns [47]. The absolute KL-
6/MUC1 serum levels at the onset of D-ILDs increased only in
life-threatening disease types, such as those ILDs displaying
diffuse alveolar damage (DAD) and chronic interstitial pneu-
monia (CIP) patterns. Serum KL-6/MUC1 levels increased or
decreased in accordance with the clinical outcome of the
disease in patients with the DAD and CIP patterns. Recently,
the clinical records and radiographs of 341 patients with
advanced NSCLCs who were treated with EGFR-TKIs were
retrospectively reviewed, and changes in serum KL-6/MUC1
levels were also monitored in patients who developed D-ILDs
[86]. Although absolute KL-6/MUC1 serum levels could not
discriminate between life-threatening and non-life-threaten-
ing D-ILDs at either the baseline reading or the onset of
D-ILDs, the ratio of the serum KL-6/MUC1 level at the onset of
D-ILDs to that at the baseline could clearly discriminate
between the 2 outcomes.
6.6. ARDS
ARDS is characterized by the influx of protein-rich edema
fluid into air spaces, with the influx resulting from the
increased permeability of the alveolar–capillary barrier. A
previous study examined KL-6/MUC1 levels in the serum and
pulmonary ELF or bronchoalveolar lavage fluid (BALF) of
patients with ARDS or acute lung injury (ALI) [87,88]. These
studies reported that the KL-6/MUC1 levels in these samples
were significantly higher in nonsurvivors than in survivors.
A recent study from our laboratory evaluated the levels of
KL-6/MUC1 in ELF and serum obtained at multiple time points
from patients with ARDS [50]. A comparison of the kinetics of
KL-6/MUC1 levels in ELF and serum between survivors and
nonsurvivors revealed that only the KL-6/MUC1 levels in ELF
on days 0–3 after the diagnosis of ARDS were significantly
higher in nonsurvivors than in survivors. In another study
from our laboratory, KL-6/MUC1 serum levels, serially mea-
sured in patients with ARDS, along with the indices of
respiratory failure, inflammation, coagulation, fibrinolysis,
and multiple organ dysfunctions were shown to be associated
with the development of disseminated intravascular coagula-
tion (DIC) [49].
The expression of MUC1-associated sialyl Lewisa has been
demonstrated in previous studies [89–91], and studies from
our laboratory have also found the presence of sialyl Lewisa
on KL-6/MUC1 [54,92]. This KL-6/MUC1 molecule containing
sialyl Lewisa was designated as SLAK, and an ELISA system
using both anti-sialyl Lewisa and anti-KL-6 antibodies was
developed to measure SLAK levels in samples. The serum
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in predicting future development of DIC [92].
6.7. Pulmonary sarcoidosis
Sarcoidosis is a chronic systemic disorder characterized by
noncaseating epithelioid cell granulomas and the accumulation
of T-lymphocytes and macrophages in multiple organs [93]. The
serum levels of KL-6/MUC1 in patients with sarcoidosis are
increased and significantly influenced by the severity of lung
involvement and the positive uptake of 67Ga-citrate in the
diseased lung [42]. Janssen et al. evaluated the ability of serum
KL-6/MUC1, SP-D, and Clara cell 16 (CC16) levels to discriminate
between patients with sarcoidosis and control subjects and
concluded that KL-6/MUC1 was the best discriminative biomar-
ker [94]. The investigators also observed a trend in which the
serum KL-6/MUC1 levels were associated with pulmonary
disease outcomes in the patients with sarcoidosis. In another
study evaluating the significance of various biomarkers in
patients with pulmonary sarcoidosis, Miyoshi et al. measured
the serum levels of KL-6/MUC1, serum amyloid A, soluble
interleukin 2 receptor, lysozyme, and angiotensin-converting
enzyme [95]. These researchers demonstrated that KL-6/MUC1
serum levels were significantly correlated with the number of
the total cells, lymphocytes, and CD4þ T lymphocytes in BALF
and were the single indicator of increased parenchymal
infiltration in chest radiographs.7. Mechanism for blood uptake of KL-6/MUC1
The primary cellular source of KL-6/MUC1 in the affected
lungs of patients with ILDs is regenerating type II pneumo-
cytes [15,29], and KL-6/MUC1 is present at high concentra-
tions in BALF [40]. KL-6/MUC1 levels in BALF were
significantly correlated with the total cell number, lympho-
cytes, neutrophils, and albumin concentrations in BALF and
with serum KL-6/MUC1 levels in patients with ILDs. A
correlation between KL-6/MUC1 serum levels and albumin
levels in BALF was also found in patients with chronic
beryllium disease, suggesting the utility of serum KL-6/
MUC1 levels as a marker for the permeability of the
air–blood barrier [96]. Both the destruction of the
alveolar–capillary barrier and the enhancement of alveolar-Table 4 – Acute phase reactant and serum KL-6 levels as seru
KL-6
Normal range
Normal range Inactive
Acute phase reactant Increased Inflammation (7  þ)
Epithelial barrier dama
 Alveolar remodeling
 Mild to severe respircapillary permeability are thought to be necessary for the
leakage of KL-6/MUC1 into systemic circulation, since KL-6/
MUC1 is a high-molecular-weight glycoprotein. As shown in
Fig. 1c, the increase in serum KL-6/MUC1 levels in patients
with ILDs results from an increase in KL-6/MUC1 production
by regeneration of alveolar type II pneumocytes and/or
enhancement of permeability following destruction of the
alveolar–capillary barrier in the affected lung.
Simultaneous measurement of the serum levels of KL-6/
MUC1, SP-A, and SP-D in patients with ILDs sometimes
reveals a discrepancy between these serum markers. For
instance, a transient increase in the serum levels of SP-A and
SP-D following mild lung injury is frequently observed, while
serum KL-6/MUC1 levels remain unchanged [8]. This discre-
pancy suggests that increases in serum KL-6/MUC1 levels do
not reflect the intensity of inflammation, but rather indicate
the extent of damaged alveolar epithelium and alveolar-
capillary permeability (Table 4).8. Association between serum KL-6/MUC1
levels and genetic variants in the MUC1 gene
Measurements of serum KL-6/MUC1 levels have been per-
formed primarily in Japanese populations, and therefore, the
data for non-Japanese populations are rather limited. We
recently found that the levels of circulating KL-6/MUC1 were
higher in European populations than in Japanese populations
[97–100]. Another recent study evaluating the relationship
between the functional A-to-G polymorphism at nucleotide
position 568 (exon 2; rs4072037) in the MUC1 gene and serum
KL-6/MUC1 levels in Caucasian subjects revealed that the
genotype of this polymorphism affected serum KL-6/MUC1
levels. KL-6/MUC1 levels were highest for the GG genotype,
lowest for the AA genotype, and in an intermediate range for
the AG genotype [100]. The HapMap data (http://hapmap.
ncbi.nlm.nih.gov/) indicate that the distributions of the AA,
AG, and GG genotypes differ between European subjects
(30.1%, 55.8%, and 14.2%, respectively) and Japanese subjects
(69.8%, 25.6%, and 4.7%, respectively). These observations
suggest an ethnic difference in the serum levels of KL-6/MUC1
and imply that a different cut-off level for KL-6/MUC1 is
needed in Caucasians to discriminate between patients with
ILDs and healthy subjects.m indicators for the activity of interstitial lung diseases.
Increased
Inflammation (–)
Insufficient repair of damaged alveoli
 Progressing alveolar remodeling
Inflammation (7  þ)
ge (–) Presence of alveolar damage
(–)  Rapid progression of alveolar remodeling
atory dysfunction  Severe clinical manifestation
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In this review, we summarized the utility of KL-6/MUC1 in the
clinical management of patients with various types of ILDs.
Based on the results from a number of reports investigating
KL-6/MUC1, the serum levels of KL-6/MUC1 are thought to be
useful for (1) detecting the presence of disease, (2) evaluating
disease activity, and (3) predicting outcomes in various types
of ILDs. Because themeasurement of serum KL-6/MUC1 levels
is rapid, inexpensive, reproducible, less invasive, and easier to
perform than SLB, HRCT, BAL, and pulmonary function tests,
we believe that this biomarker would provide a significant
benefit to the clinical management of patients with ILDs.
In Japan, KL-6/MUC1 has been used in clinical practice for
more than 10 years; however, evidence from clinical trials
validating the clinical efficacy of KL-6/MUC1 remains limited.
In addition, we are aware of ethnic differences in the
prevalence of pulmonary diseases such as D-ILDs and cystic
fibrosis [85,101,102] and in the serum levels of KL-6/MUC1
[97–100]. In order to establish KL-6/MUC1 as an internationally
useful serum biomarker, further prospective and international
studies to determine the clinical efficacy of KL-6/MUC1 in the
management of patients with ILDs are necessary.Conflict of interest
Nobuoki Kohno received patent royalties/licensing fees from
Eisai Co., Ltd.
Nobuhisa Ishikawa, Noboru Hattori, Akihito Yokoyama,
they have no potential conflict of interest.Acknowledgments
This work was supported by the Grants-in-Aid for Scientific
Research from the Ministry of Education, Culture, Sports,
Science, and Technology of Japan. The authors appreciate
insightful suggestions from Y. Ohtsuki (Matsuyama-Shimin
Hospital, Matsuyama, Japan) regarding the figures.
R E F E R E N C E S
[1] American Thoracic Society. Idiopathic pulmonary fibrosis:
diagnosis and treatment. International consensus statement.
American Thoracic Society (ATS), and the European Respira-
tory Society (ERS). Am J Respir Crit Care Med 2000;161:646–64.
[2] American Thoracic Society. European Respiratory Society.
American Thoracic Society/European Respiratory Society
International Multidisciplinary Consensus Classification of
the Idiopathic Interstitial Pneumonias. This joint statement
of the American Thoracic Society (ATS), and the European
Respiratory Society (ERS) was adopted by the ATS board of
directors, June 2001 and by the ERS Executive Committee,
June 2001. Am J Respir Crit Care Med 2002;165:277–304.
[3] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/
ALAT statement: idiopathic pulmonary fibrosis: evidence-
based guidelines for diagnosis and management. Am J Respir
Crit Care Med 2011;183:788–824.[4] Kinnula VL, Ishikawa N, Bergmann U, et al. Proteomic
approaches for studying human parenchymal lung diseases.
Expert Rev Proteomics 2009;6:619–29.
[5] King Jr. TE. Clinical advances in the diagnosis and therapy of
the interstitial lung diseases. Am J Respir Crit Care Med
2005;172:268–79.
[6] Kim R, Meyer KC. Therapies for interstitial lung disease: past,
present and future. Ther Adv Respir Dis 2008;2:319–38.
[7] British Thoracic Society recommendation. The diagnosis,
assessment and treatment of diffuse parenchymal lung
disease in adults. Thorax 1999;54(Suppl 1):S1–14.
[8] Nukiwa T. The role of biomarkers in management of
interstitial lung disease: implication of biomarkers derived
from type II pneumocytes. In: Du Bois RM, Richeldi L, editors.
The European Respiratory Monograph 46 Interstitial lung
disease. Leeds: Maney Publishing; 2009. p. 47–66.
[9] Tzouvelekis A, Kouliatsis G, Anevlavis S, et al. Serum
biomarkers in interstitial lung diseases. Respir Res 2005;6:78.
[10] Prasse A, Mu¨ller-Quernheim J. Non-invasive biomarkers in
pulmonary fibrosis. Respirology 2009;14:788–95.
[11] Thomeer M, Grutters JC, Wuyts WA, et al. Clinical use of
biomarkers of survival in pulmonary fibrosis. Respir Res
2010;11:89.
[12] van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum
biomarkers in idiopathic pulmonary fibrosis. Pulm Pharma-
col Ther 2010;23:515–20.
[13] Barlo NP, van Moorsel CH, van den Bosch JM, et al. Predicting
prognosis in idiopathic pulmonary fibrosis. Sarcoidosis Vasc
Diffuse Lung Dis 2010;27:85–95.
[14] Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble
tumor-associated antigens in sera and effusions using novel
monoclonal antibodies, KL-3 and KL-6, against lung adeno-
carcinoma. Jpn J Clin Oncol 1988;18:203–16.
[15] Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of
interstitial pneumonitis activity. Sialylated carbohydrate
antigen KL-6. Chest 1989;96:68–73.
[16] Kohno N, Inoue Y, Hamada H, et al. Difference in sero-
diagnostic values among KL-6-associated mucins classified
as cluster 9. Int J Cancer Suppl 1994;8:81–3.
[17] Stahel RA, Gilks WR, Lehmann HP, et al. Third International
Workshop on Lung Tumor and Differentiation Antigens:
overview of the results of the central data analysis. Int J
Cancer 1994;8:6–26.
[18] Hirasawa Y, Kohno N, Yokoyama A, et al. KL-6, a human
MUC1 mucin, is chemotactic for human fibroblasts. Am J
Respir Cell Mol Biol 1997;17:501–7.
[19] Seko A, Ohkura T, Ideo H, et al. Novel O-linked glycans
containing 6’sulfo-Gal/GalNAc of MUC1 secreted from human
breast cancer YMBS cells: possible carbohydrate epitopes of KL-
6(MUC1) monoclonal antibody. Glycobiology 2012;22:181–95.
[20] Singh PK, Hollingsworth MA. Cell surface-associated mucins
in signal transduction. Trends Cell Biol 2006;16:467–76.
[21] Hattrup CL, Gendler SJ. Structure and function of the cell
surface (tethered) mucins. Annu Rev Physiol 2008;70:431–57.
[22] Thathiah A, Blobel CP, Carson DD. Tumor necrosis factor-
alpha converting enzyme/ADAM 17 mediates MUC1 shed-
ding. J Biol Chem 2003;278:3386–94.
[23] Kondo K, Kohno N, Yokoyama A, et al. Decreased MUC1
expression induces E-cadherin-mediated cell adhesion of
breast cancer cell lines. Cancer Res 1998;58:2014–19.
[24] Doi M, Yokoyama A, Kondo K, et al. Anti-tumor effect of the
anti-KL-6/MUC1 monoclonal antibody through exposure of
surface molecules by MUC1 capping. Cancer Sci 2006;97:420–9.
[25] Ohshimo S, Yokoyama A, Hattori N, et al. KL-6, a human
MUC1 mucin, promotes proliferation and survival of lung
fibroblasts. Biochem Biophys Res Commun 2005;338:1845–52.
R E S P I R ATO RY I N V E S T I G AT I O N 50 ( 2012 ) 3 –1312[26] Kohno N. Serum marker KL-6/MUC1 for the diagnosis and
management of interstitial pneumonitis. J Med Invest
1999;46:151–8.
[27] Tanaka S, Hattori N, Ishikawa N, et al. Krebs von den
Lungen-6 (KL-6) is a prognostic biomarker in patients with
surgically resected nonsmall cell lung cancer. Int J Cancer
2012;130:377–87.
[28] Yamasaki H, Ikeda S, Okajima M, et al. Expression and
localization of MUC1, MUC2, MUC5AC and small intestinal
mucin antigen in pancreatic tumors. Int J Oncol 2004;24:107–13.
[29] Ohtsuki Y, Fujita J, Hachisuka Y, et al. Immunohistochemical
and immunoelectron microscopic studies of the localization
of KL-6 and epithelial membrane antigen (EMA) in presum-
ably normal pulmonary tissue and in interstitial pneumonia.
Med Mol Morphol 2007;40:198–202.
[30] Ohtsuki Y, Nakanishi N, Fujita J, et al. Immunohistochemical
distribution of SP-D, compared with that of SP-A and KL-6, in
interstitial pneumonias. Med Mol Morphol 2007;40:163–7.
[31] Hisata S, Kimura Y, Shibata N, et al. A normal range of KL-6/
MUC1 independent of elevated SP-D indicates a better prognosis
in the patients with honeycombing on high-resolution com-
puted tomography. Pulm Med 2011;2011:806014.
[32] Tanimoto T, Tanaka S, Haruma K, et al. MUC1 expression in
intramucosal colorectal neoplasms. Possible involvement in
histogenesis and progression. Oncology 1999;56:223–31.
[33] Hiraga Y, Tanaka S, Haruma K, et al. Immunoreactive MUC1
expression at the deepest invasive portion correlates with
prognosis of colorectal cancer. Oncology 1998;55:307–19.
[34] Inagaki Y, Xu H, Nakata M, et al. Clinicopathology of
sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal,
hepatic and pancreatic cancers. Biosci Trends 2009;3:220–32.
[35] Sakurai J, Hattori N, Nakajima M, et al. Differential
expression of the glycosylated forms of MUC1 during lung
development. Eur J Histochem 2007;51:95–102.
[36] Sun AP, Ohtsuki Y, Fujita J, et al. KL-6, a human MUC1 mucin, is
expressed early in premature lung. Respir Med 2003;97:964–9.
[37] Kitamura S, Hiwada K, Kobayashi J, et al. [Use of the ED046
kit to analyze serum KL-6 in patients with pneumonitis]
[Article in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi
1996;34:639–45.
[38] Kohno N, Hamada H, Fujioka S, et al. Circulating antigen KL-
6 and lactate dehydrogenase for monitoring irradiated
patients with lung cancer. Chest 1992;102:117–22.
[39] Hamada H, Kohno N, Akiyama M, et al. Monitoring of serum
KL-6 antigen in a patient with radiation pneumonia. Chest
1992;101:858–60.
[40] Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like
glycoprotein, in bronchoalveolar lavage fluid from patients with
interstitial lung disease. Am Rev Respir Dis 1993;148:637–42.
[41] Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial
pneumonia. Chest 1995;108:311–15.
[42] Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active
pneumonitis in pulmonary sarcoidosis. Chest 1996;109:1276–82.
[43] Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6
predicts the outcome of rapidly progressive idiopathic pulmon-
ary fibrosis. Am J Respir Crit Care Med 1998;158:1680–4.
[44] Takahashi T, Munakata M, Suzuki I, et al. Serum and
bronchoalveolar fluid KL-6 levels in patients with pulmonary
alveolar proteinosis. Am J Respir Crit Care Med 1998;158:1294–8.
[45] Ishikawa N, Kondo K, Oguri T, et al. Usefulness of the
modified lavage technique of Bingisser and KL-6 monitoring
in a patient with pulmonary alveolar proteinosis. Intern Med
2002;41:381–5.
[46] Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study
of KL-6, surfactant protein-A, surfactant protein-D, and
monocyte chemoattractant protein-1 as serum markers for
interstitial lung diseases. Am J Respir Crit Care Med 2002;165:
378–81.[47] Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6
levels in patients with drug induced pneumonitis. Thorax
2003;58:872–5.
[48] Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of
circulating KL-6 in idiopathic pulmonary fibrosis. Respirology
2006;11:164–8.
[49] Nakashima T, Yokoyama A, Ohnishi H, et al. Circulating
KL-6/MUC1 as an independent predictor for disseminated
intravascular coagulation in acute respiratory distress syn-
drome. J Intern Med 2008;263:432–9.
[50] Kondo T, Hattori N, Ishikawa N, et al. KL-6 concentration in
pulmonary epithelial lining fluid is a useful prognostic
indicator in patients with acute respiratory distress syn-
drome. Respir Res 2011;12:32.
[51] Inoue Y, Nishimura K, Shiode M, et al. Evaluation of serum
KL-6 levels in patients with pulmonary tuberculosis. Tuber
Lung Dis 1995;76:230–3.
[52] Ishikawa N, Hattori N, Yokoyama A, et al. Usefulness of
monitoring the circulating Krebs von den Lungen-6 levels to
predict the clinical outcome of patients with advanced
nonsmall cell lung cancer treated with epidermal growth
factor receptor tyrosine kinase inhibitors. Int J Cancer
2008;122:2612–20.
[53] Ogawa Y, Ishikawa T, Ikeda K, et al. Evaluation of serum
KL-6, a mucin-like glycoprotein, as a tumor marker for breast
cancer. Clin Cancer Res 2000;6:4069–72.
[54] Inata J, Hattori N, Yokoyama A, et al. Circulating KL-6/MUC1
mucin carrying sialyl Lewisa oligosaccharide is an indepen-
dent prognostic factor in patients with lung adenocarcino-
ma. Int J Cancer 2007;120:2643–9.
[55] Ishii H, Mukae H, Kadota J, et al. High serum concentrations
of surfactant protein A in usual interstitial pneumonia
compared with non-specific interstitial pneumonia. Thorax
2003;58:52–4.
[56] Sakamoto K, Taniguchi H, Kondoh Y, et al. Serum KL-6 in
fibrotic NSIP: Correlations with physiologic and radiologic
parameters. Respir Med 2010;104:127–33.
[57] Ichiyasu H, Ichikado K, Yamashita A, et al. Pneumocyte
biomarkers KL-6 and surfactant protein D reflect the distinct
findings of high-resolution computed tomography in non-
specific interstitial pneumonia. Respiration 2012;83:190–7.
[58] Satoh H, Kurishima K, Ishikawa H, et al. Increased levels of
KL-6 and subsequent mortality in patients with interstitial
lung diseases. J Intern Med 2006;260:429–34.
[59] Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal
clinical dilemmas in collagen vascular diseases associated with
interstitial lung involvement. Eur Respir J 2009;33:882–96.
[60] Oyama T, Kohno N, Yokoyama A, et al. Detection of
interstitial pneumonitis in patients with rheumatoid arthri-
tis by measuring circulating levels of KL-6, a human MUC1
mucin. Lung 1997;175:379–85.
[61] Nakajima H, Harigai M, Hara M, et al. KL-6 as a novel serum
marker for interstitial pneumonia associated with collagen
diseases. J Rheumatol 2000;27:1164–70.
[62] Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a
useful marker for evaluating pulmonary fibrosis in patients
with systemic sclerosis. J Rheumatol 2000;27:930–4.
[63] Yanaba K, Hasegawa M, Hamaguchi Y, et al. Longitudinal
analysis of serum KL-6 levels in patients with systemic
sclerosis: association with the activity of pulmonary fibrosis.
Clin Exp Rheumatol 2003;21:429–36.
[64] Yanaba K, HasegawaM, Takehara K, et al. Comparative study
of serum surfactant protein-D and KL-6 concentrations in
patients with systemic sclerosis as markers for monitoring
the activity of pulmonary fibrosis. J Rheumatol 2004;31:
1112–20.
[65] Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary
and activation-regulated chemokine/CCL18 levels in patients
R E S P I R ATO RY I N V E S T I G AT I O N 50 ( 2012 ) 3 –13 13with systemic sclerosis: a sensitive indicator of active
pulmonary fibrosis. Arthritis Rheum 2005;52:2889–96.
[66] Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant
protein D and KL-6 as serum biomarkers of interstitial lung
disease in patients with scleroderma. J Rheumatol 2009;36:
773–80.
[67] Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes
of KL-6 in sera of patients with interstitial pneumonia
associated with polymyositis/dermatomyositis. Ann Rheum
Dis 2000;59:257–62.
[68] Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients
with polymyositis and dermatomyositis. Rheumatology (Ox-
ford) 2000;39:632–6.
[69] Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D
and KL-6 serum levels in systemic sclerosis: correlation with
lung and systemic involvement. Sarcoidosis Vasc Diffuse
Lung Dis 2011;28:27–33.
[70] Stuck AE, Minder CE, Frey FJ. Risk of infectious complications
in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:
954–63.
[71] Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current
evidence for the management of rheumatoid arthritis with
biological disease-modifying antirheumatic drugs: a sys-
tematic literature review informing the EULAR recommenda-
tions for the management of RA. Ann Rheum Dis 2010;69:
976–86.
[72] Hamada H, Kohno N, Yokoyama A, et al. KL-6 as a serologic
indicator of Pneumocystis carinii pneumonia in immunocom-
promised hosts. Intern Med 1998;37:307–10.
[73] Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators
for the diagnosis of Pneumocystis pneumonia. Chest
2007;131:1173–80.
[74] Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in
interstitial pneumonia with and without Pneumocystis jirovecii
colonization: a prospective study. BMC Infect Dis 2009;9:47.
[75] Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of
serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii
pneumonia. Intern Med 2009;48:195–202.
[76] Bourke SJ, Dalphin JC, Boyd G, et al. Hypersensitivity
pneumonitis: current concepts. Eur Respir J Suppl 2001;32:
81s–92s.
[77] Richerson HB, Bernstein IL, Fink JN, et al. Guidelines for the
clinical evaluation of hypersensitivity pneumonitis. Report of
the Subcommittee on Hypersensitivity Pneumonitis. J Allergy
Clin Immunol 1989;84:839–44.
[78] Takahashi T, Munakata M, Ohtsuka Y, et al. Serum KL-6
concentrations in dairy farmers. Chest 2000;118:445–50.
[79] Tsushima K, Furuya S, Yoshikawa S, et al. Therapeutic
effects for hypersensitivity pneumonitis induced by Japanese
mushroom (Bunashimeji). Am J Ind Med 2006;49:826–35.
[80] Yoshikawa S, Tsushima K, Yasuo M, et al. Hypersensitivity
pneumonitis caused by Penicillium citrinum, not Enoki spores.
Am J Ind Med 2007;50:1010–17.
[81] Inase N, Ohtani Y, Usui Y, et al. Chronic summer-type
hypersensitivity pneumonitis: clinical similarities to idio-
pathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis
2007;24:141–7.
[82] Goto K, Kodama T, Sekine I, et al. Serum levels of KL-6 are
useful biomarkers for severe radiation pneumonitis. Lung
Cancer 2001;34:141–8.
[83] Hara R, Itami J, Komiyama T, et al. Serum levels of KL-6 for
predicting the occurrence of radiation pneumonitis after
stereotactic radiotherapy for lung tumors. Chest 2004;125:
340–4.
[84] Yamashita H, Kobayashi-Shibata S, Terahara A, et al.
Prescreening based on the presence of CT-scan abnormalities
and biomarkers (KL-6 and SP-D) may reduce severe radiationpneumonitis after stereotactic radiotherapy. Radiat Oncol
2010;5:32.
[85] Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease
in Japanese patients with lung cancer: a cohort and nested
case–control study. Am J Respir Crit Care Med 2008;177:
1348–57.
[86] Kawase S, Hattori N, Ishikawa N, et al. Change in serum KL-6
level from baseline is useful for predicting life-threatening
EGFR-TKIs induced interstitial lung disease. Respir Res
2011;12:97.
[87] Ishizaka A, Matsuda T, Albertine KH, et al. Elevation of KL-6,
a lung epithelial cell marker, in plasma and epithelial lining
fluid in acute respiratory distress syndrome. Am J Physiol
Lung Cell Mol Physiol 2004;286:L1088–94.
[88] Sato H, Callister ME, Mumby S, et al. KL-6 levels are elevated
in plasma from patients with acute respiratory distress
syndrome. Eur Respir J 2004;23:142–5.
[89] Baeckstro¨m D, Karlsson N, Hansson GC. Purification and
characterization of sialyl-Le(a)-carrying mucins of human
bile; evidence for the presence of MUC1 and MUC3 apopro-
teins. J Biol Chem 1994;269:14430–7.
[90] Fernandez-Rodriguez J, Dwir O, Alon R, et al. Tumor cell
MUC1 and CD43 are glycosylated differently with sialyl-Lewis
a and x epitopes and show variable interactions with E-
selectin under physiological flow conditions. Glycoconj J
2001;18:925–30.
[91] Burdick MD, Harris A, Reid CJ, et al. Oligosaccharides
expressed on MUC1 produced by pancreatic and colon tumor
cell lines. J Biol Chem 1997;272:24198–202.
[92] Nakashima T, Yokoyama A, Inata J, et al. Mucins carrying
selectin ligands as predictive biomarkers of disseminated
intravascular coagulation complication in ARDS. Chest
2010;139:296–304.
[93] Statement on sarcoidosis. Joint Statement of the American
Thoracic Society (ATS), the European Respiratory Society
(ERS) and the World Association of Sarcoidosis and Other
Granulomatous Disorders (WASOG) adopted by the ATS
Board of Directors and by the ERS Executive Committee,
February 1999. Am J Respir Crit Care Med 1999;160:736–55.
[94] Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL-
6, and surfactant protein-D in serum as disease markers in
pulmonary sarcoidosis. Chest 2003;124:2119–25.
[95] Miyoshi S, Hamada H, Kadowaki T, et al. Comparative
evaluation of serum markers in pulmonary sarcoidosis.
Chest 2010;137:1391–7.
[96] Inoue Y, Barker E, Daniloff E, et al. Pulmonary epithelial cell
injury and alveolar-capillary permeability in berylliosis. Am J
Respir Crit Care Med 1997;156:109–15.
[97] Ohshimo S, Bonella F, Grammann N, et al. Serum KL-6 as a
novel disease marker in adolescent and adult cystic fibrosis.
Sarcoidosis Vasc Diffuse Lung Dis 2009;26:47–53.
[98] Ohshimo S, Bonella F, Sommerwerck U, et al. Comparison of
serum KL-6 versus bronchoalveolar lavage neutrophilia for
the diagnosis of bronchiolitis obliterans in lung transplanta-
tion. J Heart Lung Transplant 2011;30:1374–80.
[99] Ishikawa N, Mazur W, Toljamo T, et al. Ageing and long-term
smoking affects KL-6 levels in the lung, induced sputum and
plasma. BMC Pulm Med 2011;11:22.
[100] Janssen R, Kruit A, Grutters JC, et al. The mucin-1 568
adenosine to guanine polymorphism influences serum
Krebs von den Lungen-6 levels. Am J Respir Cell Mol Biol
2006;34:496–9.
[101] Wright SW, Morton NE. Genetic studies on cystic fibrosis in
Hawaii. Am J Hum Genet 1968;20:157–69.
[102] Yamashiro Y, Shimizu T, Oguchi S, et al. The estimated
incidence of cystic fibrosis in Japan. J Pediatr Gastroenterol
Nutr 1997;24:544–7.
